Ropinirole
It is an orally administered anti-Parkinsonion drug.Treatment of signs and symptoms of idiopathic Parkinson's disease specially for patients who have developed on/off phenomenon.
1st week 0.25gm t.i.d., 2nd week 0.5mg t.i.d., 3rd week 0.75mg t.i.d., 4th week 1mg t.i.d. After week 4, daily dosage may be increased 1.5mg per day on a weekly basis up to a dose of 9mg per day, and then by up to 3mg per day weekly to a total dose of 24 mg per day.
Known hypersensitivity to the drug or its components.
Monitor the patient for orthostatic hypotension specially during dose escalation, concomitant therapy with CNS depressants should be done cautiously, titrate cautiously in patients with hepatic impairment, nausea may be decreased by taking along with food. Use with caution in patients doing jobs requiring high mental alertness because it causes somnolence and impaired motor performance.
Dyskinesia, othostatic hypotension, nausea, dizziness, somnolence, dyspepsia, hallucinations, constipation, asthenia.
Oestrogens decrease the oral clearance of ropinirole thereby increasing its plasma levels. Cimetidine, ciprofloxacin, Diltiazem and mexiletene increase its levels by altering the clearance. Phenothiazines and butyrophenones decrease its effectiveness.
